Mizuho analyst Graig Suvannavejh yesterday lowered the firm’s price target on Verastem (VSTM) to $8 from $9 and keeps an Outperform rating on the shares. The firm updated the company’s model ahead of an expected product launch for avutometinib plus defactinib in low grade serous ovarian cancer.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VSTM:
- Verastem Oncology Reports Progress in Cancer Treatments
- Verastem price target raised to $14 from $13 at Guggenheim
- Verastem’s Promising Financial Outlook and Strategic Advancements Drive Buy Rating
- Verastem price target raised to $10 from $7 at H.C. Wainwright
- Verastem price target lowered to $14 from $16 at RBC Capital